The 2021 Marketer of the Year competition will be closing for entry on the 10th of September.
News
Enhertu improves progression-free survival in breast cancer trial
Trial compared Enhertu with T-DM1 in patients with HER2-positive breast cancer
US approval for Sanofi’s late-onset Pompe disease med Nexviazyme
The enzyme replacement therapy is designed to target the key mannose-6-phosphate receptor pathway
Interim trial data for UCB’s bimekizumab shows positive results
High levels of skin clearance achieved for moderate to severe plaque psoriasis patients
AZ’s Forxiga gains EC, MHRA approvals for chronic kidney disease
Approval based on DAPA-CKD Phase III data
Finalists announced for CROY 2021
The finalists have been confirmed for the 2021 Clinical Researcher of the Year – The Americas competition.
Bayer buys Vividion Therapeutics for up to $2bn
Acquisition strengthens Bayer’s drug discovery capabilities
Sanofi and Regeneron’s Libtayo trial stops early due to survival improvement
Libtayo plus platinum-doublet chemotherapy led to a 29% reduction in risk of death compared to chemotherapy alone
Sierra Oncology licenses myelofibrosis candidate from AstraZeneca
Planned Phase II study to combine the BET inhibitor with momelotinib
Pfizer, Flynn accused of charging the NHS ‘unfairly high prices’ for anti-epilepsy drug
UK Competition and Markets Authority provisionally finds drug companies broke competition law
Report finds reducing primary care antibiotic use ‘not enough’ to halt antimicrobial resistance
Drug resistant E. coli infections were not halted by reduction, according to new report
NICE pens two-year collaboration with the Academic Health Science Network
Agreement will support use of the ‘best evidence-based healthcare’ in the NHS
Positive Phase III results for Valneva’s chikungunya vaccine
Neutralising antibody titers were observed in 98.5% of subjects
16- and 17-year-olds should receive first COVID-19 vaccine, advises JCVI
Vaccine side effects rare and outweighed by the benefits
BMS withdraws Istodax as a treatment for peripheral T-cell lymphoma
Phase III trials did not demonstrate sufficient clinical benefit.
